Question 1

What is TISLELIZUMAB-JSGR used for?

Accepted Answer

TISLELIZUMAB-JSGR (brand name TEVIMBRA) is a Other indicated for in combination with platinum-containing chemotherapy, as a single agent, in combination with platinum and fluoropyrimidine-based chemotherapy.

Question 2

How does TISLELIZUMAB-JSGR work?

Accepted Answer

TISLELIZUMAB-JSGR works through the following mechanism: 12.1 Mechanism of Action Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Tislelizumab-jsgr binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Tislelizumab-jsgr decreased tumor growth in xenograft models and a human PD-1 transgenic mouse model..

Question 3

What are the most common side effects of TISLELIZUMAB-JSGR?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for TISLELIZUMAB-JSGR. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is TISLELIZUMAB-JSGR the same as TEVIMBRA?

Accepted Answer

TEVIMBRA is a brand name for TISLELIZUMAB-JSGR. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

TISLELIZUMAB-JSGR

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations